GSK plc (LON:GSK)
2,076.00
+1.00 (0.05%)
Apr 23, 2026, 5:10 PM GMT
GSK plc Revenue
In the year 2025, GSK plc had annual revenue of 32.67B GBP with 4.11% growth. GSK plc had revenue of 8.62B in the quarter ending December 31, 2025, with 6.17% growth.
Revenue
32.67B
Revenue Growth
+4.11%
P/S Ratio
2.54
Revenue / Employee
488.73K
Employees
66,841
Market Cap
82.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.67B | 1.29B | 4.11% |
| Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
| Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
| Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
| Dec 31, 2019 | 33.75B | 2.93B | 9.52% |
| Dec 31, 2018 | 30.82B | 635.00M | 2.10% |
| Dec 31, 2017 | 30.19B | 2.30B | 8.24% |
| Dec 31, 2016 | 27.89B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.64B |
| Haleon | 11.03B |
| Smith & Nephew | 4.58B |
| Hikma Pharmaceuticals | 2.49B |
| Convatec Group | 1.81B |
| CVS Group | 692.80M |
| Genus | 672.00M |
| HUTCHMED (China) | 407.54M |
GSK plc News
- 17 hours ago - FTSE 100 Index retreats ahead of Lloyds, Barclays, Natwest, GSK earnings - Invezz
- 3 days ago - GSK Secures Approval for Blenrep in China for Multiple Myeloma Treatment - GuruFocus
- 10 days ago - GSK Reports Promising Phase I Results for Novel Cancer Treatment - GuruFocus
- 10 days ago - NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company's first Chief Commercial Officer - Benzinga
- 10 days ago - GSK Plans Five Late-Stage Cancer Trials As Shares Rise Nearly 50% - GuruFocus
- 10 days ago - GSK Reports Promising Early Data For Experimental Cancer Drug - Benzinga
- 11 days ago - GSK Announces Positive Phase I Results For Mo-Rez In Ovarian And Endometrial Cancer - Nasdaq
- 11 days ago - GSK Shifts Strategy with Five Late-Stage Trials for Promising Cancer Drug - GuruFocus